Effects of intraperitoneal heparin on peritoneal transport in a chronic animal model of peritoneal dialysis.
BACKGROUND
Heparin has anti-inflammatory effects and is often added to the peritoneal dialysis fluid to prevent fibrin formation. Conjugation of heparin to the surface of biomaterials has been shown to improve its biocompatibility. In this study, we describe for the first time an experimental chronic peritoneal dialysis model with repeated dwell studies in non-uraemic rats and evaluate the effect of addition of heparin to glucose-based peritoneal dialysis fluid on peritoneal fluid and solute transport.


METHODS
Wistar male rats, weighing 340+/-15 g, with implanted peritoneal catheters were infused during 1 month, twice per day with 20 ml of Dianeal 1.36%+antibiotics (AB; n = 10) or Dianeal 1.36%+antibiotics+heparin 2500 U/l (HAB; n = 9). After 10 (DS 1) and 30 days (DS 2), a dwell study was performed in rats with free access to drinking water, by infusing 30 ml of Dianeal 3.86%. Dialysate samples were obtained at 0, 2, 30, 60, 120 and 240 min. Blood samples were drawn before and at the end of the dwell. Radiolabelled serum albumin was used as macromolecular volume marker.


RESULTS
Peritoneal volumes during DS 1 were significantly greater for the HAB group as compared with the AB group. No differences in ultrafiltration were found during DS 2 for HAB vs AB. However, peritoneal volumes were significantly higher for DS 2 compared with DS 1 in the AB group. The amount of glucose absorbed over time did not differ between the solutions, while fluid absorption tended to be lower in the HAB group.


CONCLUSIONS
Heparin may improve peritoneal fluid transport possibly due to better healing and reduced peritoneal inflammation as shown in this novel animal model of chronic peritoneal dialysis with repeated dwell studies.
Division of Baxter Novum and Renal Medicine, Department of Clinical Science, Huddinge University Hospital, Karolinska Institutet, Stockholm, Sweden.
K
K
Pawlaczyk
M
M
Kuzlan-Pawlaczyk
B
B
Anderstam
O
O
Heimbürger
J
J
Bergström
J
J
Waniewski
A
A
Breborowicz
B
B
Lindholm
D000042:Absorption / Q000187:drug effects; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D001202:Ascitic Fluid / Q000378:metabolism; D001692:Biological Transport / Q000187:drug effects; D015314:Dialysis Solutions / Q000494:pharmacology; D005947:Glucose / Q000493:pharmacokinetics; D006493:Heparin / Q000008:administration & dosage* / Q000627:therapeutic use; D007274:Injections, Intraperitoneal; D008297:Male; D010530:Peritoneal Dialysis; D010537:Peritoneum / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar; D012996:Solutions; D013997:Time Factors
D000893:Anti-Inflammatory Agents; D015314:Dialysis Solutions; D012996:Solutions; D006493:Heparin; D005947:Glucose